Q3 2021 Financial Presentation2021-11-04 The Executive Managment in Ascelia Pharma presents a business update and the quarterly results InvestorGenväg till IR & Media IR & Media Key downloads Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA SubmissionAnnual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study CompletionQ4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 StudyQuarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study
